Key Highlights

  • Shares trading up 0.27% to $59.86 in today's session.
  • Trading Volume reached 4.95 million shares.
  • Median progression-free survival reached 42 months versus 20 months for the comparison regimen.
  • The trial showed a 51% reduction in the risk of disease progression or death.

Phase 3 Study Meets Primary Endpoint With Strong Results

Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical company with a broad oncology and immunology portfolio, announced topline results from its Phase 3 EXCALIBER-RRMM study. The trial tested ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone against a standard three-drug regimen in 800 patients with relapsed or refractory multiple myeloma.

Median Survival More Than Doubles Versus Comparison Regimen

The combination showed a 51% reduction in the risk of disease progression or death, with median progression-free survival of 42 months versus 20 months for the comparison group, meeting the study's main goal with statistical significance. The safety profile was consistent with ZENBEXUS's established data from earlier studies.

Shares Show Modest Reaction to Already-Anticipated Data

Shares were little changed today, with the modest move suggesting the market may have partly priced in the company's recent approvals in this disease area, including an earlier Accelerated Approval and a more recent expanded approval for a related combination.

Outlook: Third-Quarter Results and Patent Cliff in Focus

Investors are looking ahead to the company's third-quarter results later this month, with patent-cliff concerns for some of its older products still a key focus alongside the continued rollout of newer therapies like ZENBEXUS across additional indications.